Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957789 | 0.93 | LMNA (0.49) | MAPTLMNAMAPK14MAPK13MAPK11 | |
| SCHEMBL2960293 | 0.89 | LMNA (0.47) | MAPTLMNAMAPK14MAPK13MAPK11 | |
| SCHEMBL4601552 | 0.89 | MAPK14 (0.55) | MAPTLMNAMAPK14MAPK13MAPK11 | |
| SCHEMBL2957020 | 0.88 | MAPK14 (0.47) | MAPTLMNAMAPK14MAPK13MAPK11 | |
| SCHEMBL4603086 | 0.88 | NTRK1 (0.49) | MAPTLMNAMAPK14MAPK13MAPK11 | |
| SCHEMBL2959949 | 0.88 | MAPK14 (0.47) | MAPTLMNAMAPK14MAPK13MAPK11 | |
| SCHEMBL2960044 | 0.87 | MAPT (0.46) | MAPTLMNAMAPK14MAPK13MAPK11 | |
| SCHEMBL2953737 | 0.86 | MAPT (0.49) | MAPTLMNAMAPK14MAPK13MAPK11 | |
| SCHEMBL2955752 | 0.86 | MAPK14 (0.48) | MAPTLMNAMAPK14MAPK13MAPK11 | |
| SCHEMBL2958116 | 0.86 | MAPK14 (0.50) | MAPTLMNAMAPK14MAPK13MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767674-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2010-08-03 | — | — | US | disclosed |
| US-20080306068-A1 | Suppression cytokines, tumor necrosis factor | ELI LILLY AND COMPANY (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1761520-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306068-A1 | Suppression cytokines, tumor necrosis factor | TNF, TNFRSF1A, IL2 | MAPT 4665/4885LMNA 4573/4885MAPK14 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.